Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 232 |
| Active Pipeline (Recruiting Now) | 71 (42) |
| Completed vs Stopped Early | 77 / 24 (10.3%) |
| Median Closed Actual Enrollment | 187 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Fudan University Shanghai Cancer Center | Shanghai, Shanghai Municipality | 24 |
| Beijing Cancer Hospital | Beijing, Beijing Municipality | 14 |
| Zhejiang Cancer Hospital | Hangzhou, Zhejiang | 12 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07286032 | A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia | Phase III | RECRUITING |
| NCT03588091 | Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer | Phase III | COMPLETED |
| NCT04447118 | Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platin | Phase III | COMPLETED |
| NCT04300114 | A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Pla | Phase III | TERMINATED |
Explore interactive annual charts and M&A subsidiary rollups in the Jiangsu HengRui Medicine Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.